Ipamorelin vs CJC-1295: Same Goal, Very Different Biology

Up to 43 percent of your IGF-1 response to a growth hormone peptide is genetically determined before you inject a single dose. The standard protocol guides skip this entirely. They tell you to pick ipamorelin or CJC-1295, or better yet stack both, and titrate from 100 to 300 mcg. What they skip is the reason two people on identical protocols can see results that differ by nearly half a standard deviation in IGF-1 elevation: the answer is already written in their genome.

That said, genetics is the second question here, not the first. The first question is whether you understand what these two peptides actually do, because most people comparing them do not realize they operate on completely different parts of the same system. Ipamorelin triggers GH release. CJC-1295 increases the body's capacity to produce GH. The distinction sounds minor. In practice, it determines everything about how you should use them.

Ipamorelin is a GH-releasing peptide (GHRP). It mimics ghrelin and binds the GHSR-1a receptor to trigger a discrete GH pulse from your pituitary. The pulse is fast and clean: in the first human pharmacokinetic study by Raun et al. (European Journal of Endocrinology, 1998, PMID 9849822), a single dose elevated GH concentrations from a baseline of 11 mU/L to a range of 20 to 223 mU/L depending on dose, peaking at roughly 40 minutes. Critically, even at doses 200-fold above the effective threshold, ipamorelin produced no meaningful increase in cortisol or ACTH. This selectivity was unprecedented among GHRP compounds tested at the time, and it remains ipamorelin's defining clinical advantage.

CJC-1295 is a different animal entirely. It is a GHRH analogue, meaning it mimics growth hormone-releasing hormone and binds the GHRHR receptor, which is not the same receptor ipamorelin targets. Where ipamorelin triggers a pulse, CJC-1295 extends and amplifies the body's own baseline GH production by keeping GHRH active far longer than it would naturally persist. The result, documented in the only major human trial by Teichman et al. (Journal of Clinical Endocrinology and Metabolism, 2006, DOI: 10.1210/jc.2005-1500), is a GH elevation that lasts not 40 minutes but six or more days from a single injection, with IGF-1 elevated 1.5 to 3-fold and remaining above baseline for 9 to 11 days.

What do the human studies actually show?

The honest answer is: less than most peptide content implies. Ipamorelin and CJC-1295 are each supported by a small number of human studies, and there are no published head-to-head trials comparing them directly. The strongest human data for each comes from specific, limited contexts.

For ipamorelin, the Raun et al. 1998 pharmacokinetics study confirmed dose-proportional GH release and the cortisol-selectivity profile. A 1999 PK/PD modeling study by Gobburu et al. (Pharmaceutical Research, PMID 10496658) validated the terminal half-life of approximately two hours and a dose-proportional response curve that makes ipamorelin relatively predictable at clinical doses. These two studies establish the pharmacological profile. They do not establish long-term body composition or performance outcomes in humans.

For CJC-1295, the Teichman et al. 2006 JCEM trial provides the most meaningful human data in the peptide category. The trial involved healthy adult subjects receiving subcutaneous CJC-1295 at doses of 30 to 120 mcg/kg. Results were striking:

CJC-1295 increased mean plasma GH concentrations 2- to 10-fold for 6 or more days and mean IGF-1 concentrations 1.5- to 3-fold for 9-11 days after a single injection. Multiple doses of CJC-1295 resulted in IGF-1 levels that were elevated for 28 days or more with no serious adverse events at any dose tested.

Teichman et al., Journal of Clinical Endocrinology and Metabolism, 2006, DOI: 10.1210/jc.2005-1500

That result, sustained IGF-1 elevation from a once-weekly or twice-monthly injection, is why CJC-1295 became the foundation of most clinical GH optimization protocols. The IGF-1 elevation drives the downstream effects: increased nitrogen retention, enhanced fat oxidation, improved protein synthesis, and bone density support over weeks to months of dosing. There is no comparable sustained-IGF-1 data for ipamorelin used alone. For more context on how GH axis peptides fit into a broader protocol, the peptide stacking guide covers the layering logic and timing.

Why there is no head-to-head trial

No published controlled trial has directly compared ipamorelin and CJC-1295 in the same population. The comparison most practitioners rely on is mechanistic inference from the two separate pharmacology bodies above. The common clinical conclusion, that they are synergistic because they act on different receptors (GHSR-1a vs GHRHR), is plausible and widely used, but it rests on extrapolation rather than direct evidence. Co-administration is reported by practitioners to produce GH surges 6 to 10 times greater than either compound alone, but this figure comes from clinical observation, not controlled trials.

How do ipamorelin and CJC-1295 actually compare?

When does combining them actually make sense?

The standard answer in every peptide forum and most clinical protocols is: always combine them. The reasoning is that ipamorelin triggers acute GH pulses through GHSR-1a while CJC-1295 simultaneously raises the pituitary's capacity to respond to those signals through GHRHR. The result is a larger GH surge than either produces alone. In principle, this synergistic mechanism is real and the logic is sound.

The case against defaulting to the combination is less commonly discussed. Ipamorelin's primary clinical advantage is its selectivity: unlike GHRP-2, GHRP-6, and hexarelin, it produces clean GH elevation with no cortisol spike and no appetite stimulation. Adding CJC-1295 introduces sustained GH axis activation that is inherently less surgical. For people with normal HPA axis function and a body composition goal, the stack is probably the right call. For people with elevated baseline cortisol, adrenal fatigue, or sensitivity to sustained hormonal activation, ipamorelin alone often provides better tolerance with acceptable GH outcomes. The DNA-first decision framework walks through how to determine which category you fall into before you choose a protocol.

How your genes determine which protocol actually works

The most frequently cited metric in GH peptide discussions is IGF-1 level after 6 to 8 weeks of dosing. People compare results, adjust doses, and conclude that their protocol is working or not. What almost nobody discusses is that IGF-1 response to GH axis stimulation is not primarily a dose question. It is substantially a genetics question.

The GHR d3 polymorphism (growth hormone receptor exon 3 deletion) is the best-studied genetic predictor of GH axis responsiveness. People carrying the d3 isoform respond more strongly to GH axis stimulation in terms of IGF-1 elevation. People carrying the full-length (fl) isoform have reduced receptor sensitivity. This variant is common (roughly 25% of the population carries at least one d3 allele) and it directly predicts how much IGF-1 you will see from a CJC-1295 protocol. The peptide does its job regardless of your genotype. Your receptor is the variable that determines how large the downstream signal gets.

For ipamorelin, the relevant receptor is GHSR-1a (growth hormone secretagogue receptor). A 2025 study published in the Journal of Clinical Endocrinology and Metabolism (PMC12012706) characterized loss-of-function variants in GHSR that are associated with significantly reduced IGF-1 levels, growth impairment, and blunted GH axis signaling. These variants are rarer than the GHR d3 polymorphism (estimated prevalence 3 to 5%) but functionally significant: a loss-of-function GHSR variant means ipamorelin has substantially less receptor to work with, and the GH pulse it produces will be proportionally smaller.

What this means when choosing between the two

If your GHR genotype is fl/fl (the low-sensitivity variant), CJC-1295 will produce a blunted IGF-1 response regardless of dose. You are not failing the protocol. Your receptor is simply less sensitive to the downstream GH signal. In this case, switching to approaches that support the anabolic signaling cascade through non-GH pathways may produce better outcomes (the best peptides for healing guide covers several compounds that work through collagen, vascular, and tissue-repair mechanisms independent of the GH axis).

If your GHSR variant reduces ipamorelin binding, the pulsatile approach loses most of its clinical rationale. CJC-1295's sustained GHRHR activation bypasses the GHSR-1a receptor entirely and may produce better IGF-1 outcomes for this genotype through a different receptor axis. The key insight is that these two peptides targeting different receptors is not just a pharmacological detail. It is a genetic selection tool. Your genotype at GHR and GHSR partially determines which receptor-based approach has more ceiling to work with.

Dosing: what clinical practice looks like

Neither ipamorelin nor CJC-1295 has an FDA-approved human dose. The following reflects preclinical scaling and clinical practice patterns, not randomized dose-optimization trials.

Two practical notes. First, both peptides are typically injected subcutaneously rather than intramuscularly. Timing before sleep is standard for the combination because GH naturally peaks during deep sleep, and the combined protocol is designed to amplify that nocturnal pulse rather than replace it with a daytime signal. Second, for anyone considering a GH secretagogue protocol, blood-based IGF-1 monitoring at baseline and again at 6 to 8 weeks is the only reliable way to confirm whether the protocol is producing a measurable endocrine response. Self-reported recovery and body composition changes are subjective. Serum IGF-1 is not.

Can you legally get ipamorelin or CJC-1295 in the US right now?

This is where the 2026 picture is less optimistic than most peptide content implies. Both compounds have been in prolonged regulatory limbo since September 2023, when the FDA placed them on Category 2 of the interim 503A bulks list, effectively blocking US compounding pharmacies from producing them.

In September 2024, the FDA removed both compounds from the Category 2 list after nominators withdrew their submissions (FDA docket, September 27, 2024). This reversal sounded like progress. It was not a restoration of access. At the October 29, 2024 PCAC meeting, the committee voted against recommending ipamorelin for the 503A Bulks Regulation. CJC-1295 remains in the same post-Category-2 limbo: no longer explicitly banned, but not authorized for compounding either.

The April 2026 HHS announcement, in which Secretary Kennedy directed FDA to move 12 peptides back toward PCAC review, conspicuously excluded both ipamorelin and CJC-1295. A PCAC meeting is scheduled for July 23 to 24, 2026, but neither compound is currently on the agenda. In June 2025, an FDA Class II recall of Thrive Health Solutions' CJC-1295 injectable (reason: lack of sterility assurance) reinforced the quality-control concerns that originally drove the restrictions.

The practical bottom line: as of May 2026, neither ipamorelin nor CJC-1295 can be legally compounded under 503A in the US. Access for patients exists primarily through international compounding pharmacies, telehealth providers sourcing internationally, or research supply channels. None of these carry the FDA oversight that 503A compounding provides. If you are comparing options for a supervised GH peptide protocol and US regulatory access matters, the compounds reclassified in April 2026 (including sermorelin, a GHRH analogue with an established prescription pathway) are the legal alternatives currently available. For a full picture of how the legal landscape affects peptide selection, the DNA-first decision framework section on regulatory context covers the current 503A situation across all major compounds.

Internationally: WADA prohibits both for athletic competition, Australia's TGA classifies ipamorelin as Schedule 4 (prescription only), and neither holds EMA marketing authorization in the EU or UK. See the ipamorelin peptide page for a current breakdown of access by market.